is.......................Broke and can't be fixed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That mess has Jimmy Spencer written all over it!
AVNR
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer-Sibold Brings Accomplished Leadership Skills and Exceptional Commercial Record to Strengthen Executive Team-
ALISO VIEJO, Calif., April 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of William (Bill) Sibold to the position of senior vice president and chief commercial officer. In this newly created role, Mr. Sibold will be responsible for leading all of the company's commercial activities.
"Bill has an outstanding track record of success in biopharmaceutical sales and marketing," said Keith A. Katkin, president and CEO of Avanir. "I am delighted that we were able to attract someone of Bill's caliber to our growing organization. His proven ability to build and lead cross-functional teams, to develop and launch new products to drive growth further enhances our already strong commercial leadership team."
Mr. Sibold has over 20 years of experience in the biopharmaceutical industry and has worked on significant products including Prozac, Avonex and Tysabri. Mr. Sibold's most recent commercial leadership role was as senior vice president, U.S. Commercial for Biogen Idec Inc., where he was responsible for all commercial activities, across Biogen Idec's neurology, oncology and rheumatology U.S. businesses. Mr. Sibold also held numerous international and domestic leadership positions at Biogen Idec prior to his role as senior vice president. Prior to Biogen Idec, Mr. Sibold held a number of strategic business development, sales and marketing management roles at Innovative Clinical Solutions. Mr. Sibold's experience also includes sales and marketing positions at Eli Lilly and Amgen Inc. Most recently, Mr. Sibold was president and CEO of Lycera Corp. a preclinical phase company with two innovative oral immunomodulators. Mr. Sibold earned his MBA from Harvard Business School and his BA in Molecular Biophysics and Biochemistry from Yale University.
"I am excited to be taking on this new role," said Bill Sibold, senior vice president and chief commercial officer of Avanir. "Joining Avanir is a tremendous opportunity and I look forward to working with the commercial team to continue to build upon NUEDEXTA's early launch success and future expansion both in the U.S. and internationally."
AIS
Down nearly 2% on news that NDA has been accepted. Sell the news, perhaps?
I believe it will recover today, but it is certainly dissappointing following the poor pps reaction to the conference.
AVNR
Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting
ALISO VIEJO, Calif., April 7, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from a number of clinical research activities will be highlighted at the 63rd Annual Meeting of the American Academy of Neurology (AAN), taking place in Honolulu, HI, at the Hawaii Convention Center from April 9 through 16, 2011.
Following are details about the data presentations:
Title: Burden of Pseudobulbar Affect on Social Function and Quality of Relationships: Results of a Harris Survey
Program Number: P03.283 (Poster Presentation)
Presentation Date/Time: Tuesday, April 12, 2011, 5:00pm
Session Info: Session P03: Neurologic Manifestations III
Title: Analysis of Time to Onset of Action of Dextromethorphan/Quinidine for Treatment of Pseudobulbar Affect from a Randomized, Placebo-Controlled Trial (STAR)
Program Number: S09.007 (Oral Presentation)
Presentation Date/Time: Tuesday, April 12, 2011, 2:30pm
Session Info: Session S09: Neurologic Manifestations of Systemic Disease
About PBA
Patients suffering from existing neurological disease or brain injury may also suffer the added burden of pseudobulbar affect, or PBA. PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. PBA outbursts result from a "short circuit" in the brain caused by another neurologic condition-such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, or traumatic brain injury. PBA can have a debilitating impact on the lives of patients, caregivers and loved ones. For more information about PBA, please visit www.PBAinfo.org.
About NUEDEXTA
NUEDEXTA™ is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.
NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.
NUEDEXTA Important Safety Information
NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days. NUEDEXTA is contraindicated in patients with a known hypersensitivity to its components.
NUEDEXTA may cause serious side effects, including possible changes in heart rhythm. NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, in patients with heart failure as well as patients with, or at risk of, complete atrioventricular (AV) block, unless the patient has an implanted pacemaker.
NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk of QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3-4 hours after the first dose. The most common adverse reactions in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, weakness, swelling of feet and ankles, urinary tract infection, flu, elevated liver enzymes, and flatulence. NUEDEXTA may cause dizziness. Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls.
Patients should take NUEDEXTA exactly as prescribed. Patients should not take more than 2 capsules in a 24- hour period, make sure that there is an approximate 12-hour interval between doses, and not take a double dose after they miss a dose.
These are not all the risks from use of NUEDEXTA. For additional important safety information about NUEDEXTA, please see the full Prescribing Information at www.NUEDEXTA.com.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.
AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners
©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.
SOURCE Avanir Pharmaceuticals, Inc.
We can't pick the same drivers as everyone else and expect to move up......then again, we can always move down.
I wasn't too sure when I picked it, now that you questioned it I'm really not sure.
Thanks for planting the seed of doubt...
11
29
48
If you would please.
AIS
$heff,
Any ideas why the poor showing by AIS stock on the two days of the conference?
I made it from Palm Beach Gardens to Philly in about 19 hours once, by myself.
Mountain Dew and "pit stops" (caused by the Mountain Dew) can do wonders.....
Red,
You need to bring that ride up north, so you can climb this hill.
http://www.pahillclimb.org/Courses/Giants.htm
Feds charge corp. attorney and trader in $32 million insider trading scheme.
http://online.wsj.com/article/SB10001424052748704101604576246500048582840.html?mod=googlenews_wsj
AVNR
Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
ALISO VIEJO, Calif., April 5, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.(NASDAQ: AVNR) today announced that company management will present an overview of the company at the Future Leaders in the Biotech Industry Conference in New York City.
• Location: Millennium Broadway Hotel & Conference Center, New York, NY
• Presentation date: Friday April 15, 2011
• Presentation time: 2:00pm ET
A live webcast and 30-day archive of this presentation will be available at http://www.avanir.com.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.
AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners
©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.
SOURCE Avanir Pharmaceuticals, Inc.
My salary!
If I wasn't so surprised and lucky to be this high in the standings, I'd keep my words to myself. But I'm thinking, I'd better enjoy it while I can.
Hooray for the Gileon Express!
Still in the top ten.
YESSSSSS!!!!!
If I stay there I get to sit at the front table for the banquet.
Hey everybody GREAT NEWS!
I'll be passing Red in the standings.....lets face it, that's all that matters.
What do southerners know about stock car racing anyway?
Depomed Appoints James A. Schoeneck President and CEO
Date(s): 4-Apr-2011 7:00 AM
For a complete listing of our news releases, please click here
Menlo Park, Calif., April 4, 2011 - Depomed, Inc. (NASDAQ: DEPO) today announced the appointment of James A. Schoeneck as the company's President and CEO, effective April 18, 2011. Mr. Schoeneck, a member of the company's Board of Directors since 2007, succeeds Carl A. Pelzel, who has resigned for personal reasons.
Peter D. Staple, Chairman of Depomed's Board of Directors, said, "We are delighted that Jim has agreed to lead Depomed as the company accelerates its transition as a commercial enterprise. He has a great track record of commercial and operational achievements and developing successful business strategies. This experience will be invaluable as we leverage Depomed's considerable assets to the benefit of the company and its shareholders. During Jim's three years of Board service, he has been closely involved in overseeing our business strategy and operations. He is well positioned to assume leadership of the company." Mr. Staple added, "On behalf of the entire Board, I also want to thank Carl for his committed service and leadership that helped to transform Depomed from a development organization to a company with strong assets, momentum, and attractive growth prospects."
Mr. Schoeneck said, "I am excited to join Depomed and to work more closely with Depomed's accomplished leadership team and employees. The recent approval of GraliseTM (gabapentin) provides us with a tremendous opportunity to generate revenue growth through a direct commercial presence. Depomed is poised to build significant near-term value for all those we serve - investors, patients, physicians and payors." Mr. Schoeneck commented, "The company has approved products, a promising late-stage product candidate in Serada®, revenue from technology licenses, and over $160 million in cash."
Since 2005, Mr. Schoeneck, 53, has served as chief executive officer of BrainCells Inc., a private biopharmaceutical company in San Diego, California. Mr. Schoeneck's broad pharmaceutical experience includes three years as the president and chief executive officer of Prometheus Laboratories Inc., a specialty pharmaceutical company. At Prometheus, Mr. Schoeneck led the company to profitability and rapid revenue growth, increasing sales from $6 million to over $70 million. Under Mr. Schoeneck's leadership, Prometheus was recognized as the third fastest growing private company in America by Inc. magazine.
Prior to Prometheus, Mr. Schoeneck spent three years at Centocor, Inc., where he led the development of Centocor's commercial capabilities, growing his team from three people to almost 500 in less than three years. His group launched Remicade®, which has become the world's fifth largest selling pharmaceutical product, with over $7 billion in sales in 2010.
Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis) serving in various sales and marketing positions of increasing responsibility, including the launch of products that generated over $300 million in annual sales. Prior to joining BrainCells, he was chief executive officer of ActivX BioSciences, a development stage biotechnology company.
Conference Call
Depomed will host a conference call on Monday, April 4, 2011 at 8:00 AM EDT to further discuss the matters disclosed above.
The conference call will be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one approved product on the market and another recently approved product. GraliseTM (gabapentin) is a once-daily treatment approved for the management of post-herpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. The company also has a robust pipeline including Serada®, which is in Phase 3 clinical development for menopausal hot flashes, as well as earlier stage candidates. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for controlled release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, http://www.depomed.com.
Forward-looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements, including statements related to the Company's business prospects under new leadership, should not be regarded as a representation by Depomed that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Depomed's business, including, without limitation: risks related to the launch of GraliseTM; and other risks detailed in Depomed's prior press releases and public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Depomed does not undertake any obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
CONTACT:
Sheilah Serradell
Depomed, Inc.
(650) 462-5900
sserradell@depomed.com
DEPO
Depomed Appoints James A. Schoeneck President and CEO
Date(s): 4-Apr-2011 7:00 AM
For a complete listing of our news releases, please click here
Menlo Park, Calif., April 4, 2011 - Depomed, Inc. (NASDAQ: DEPO) today announced the appointment of James A. Schoeneck as the company's President and CEO, effective April 18, 2011. Mr. Schoeneck, a member of the company's Board of Directors since 2007, succeeds Carl A. Pelzel, who has resigned for personal reasons.
Peter D. Staple, Chairman of Depomed's Board of Directors, said, "We are delighted that Jim has agreed to lead Depomed as the company accelerates its transition as a commercial enterprise. He has a great track record of commercial and operational achievements and developing successful business strategies. This experience will be invaluable as we leverage Depomed's considerable assets to the benefit of the company and its shareholders. During Jim's three years of Board service, he has been closely involved in overseeing our business strategy and operations. He is well positioned to assume leadership of the company." Mr. Staple added, "On behalf of the entire Board, I also want to thank Carl for his committed service and leadership that helped to transform Depomed from a development organization to a company with strong assets, momentum, and attractive growth prospects."
Mr. Schoeneck said, "I am excited to join Depomed and to work more closely with Depomed's accomplished leadership team and employees. The recent approval of GraliseTM (gabapentin) provides us with a tremendous opportunity to generate revenue growth through a direct commercial presence. Depomed is poised to build significant near-term value for all those we serve - investors, patients, physicians and payors." Mr. Schoeneck commented, "The company has approved products, a promising late-stage product candidate in Serada®, revenue from technology licenses, and over $160 million in cash."
Since 2005, Mr. Schoeneck, 53, has served as chief executive officer of BrainCells Inc., a private biopharmaceutical company in San Diego, California. Mr. Schoeneck's broad pharmaceutical experience includes three years as the president and chief executive officer of Prometheus Laboratories Inc., a specialty pharmaceutical company. At Prometheus, Mr. Schoeneck led the company to profitability and rapid revenue growth, increasing sales from $6 million to over $70 million. Under Mr. Schoeneck's leadership, Prometheus was recognized as the third fastest growing private company in America by Inc. magazine.
Prior to Prometheus, Mr. Schoeneck spent three years at Centocor, Inc., where he led the development of Centocor's commercial capabilities, growing his team from three people to almost 500 in less than three years. His group launched Remicade®, which has become the world's fifth largest selling pharmaceutical product, with over $7 billion in sales in 2010.
Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis) serving in various sales and marketing positions of increasing responsibility, including the launch of products that generated over $300 million in annual sales. Prior to joining BrainCells, he was chief executive officer of ActivX BioSciences, a development stage biotechnology company.
Conference Call
Depomed will host a conference call on Monday, April 4, 2011 at 8:00 AM EDT to further discuss the matters disclosed above.
The conference call will be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one approved product on the market and another recently approved product. GraliseTM (gabapentin) is a once-daily treatment approved for the management of post-herpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. The company also has a robust pipeline including Serada®, which is in Phase 3 clinical development for menopausal hot flashes, as well as earlier stage candidates. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for controlled release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, http://www.depomed.com.
Forward-looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements, including statements related to the Company's business prospects under new leadership, should not be regarded as a representation by Depomed that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Depomed's business, including, without limitation: risks related to the launch of GraliseTM; and other risks detailed in Depomed's prior press releases and public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Depomed does not undertake any obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
CONTACT:
Sheilah Serradell
Depomed, Inc.
(650) 462-5900
sserradell@depomed.com
Red, can you change my picks to
11
18
48
Please and thank you.
18
48
99
Hike!
Well then, can I take his place? Just give me his points so far, cause I wouldn't want anyone to have to have an asterisk by their name. *****
Agreed,
I'm not claiming the article is biased, I'm claiming it is irresponsible to quote biased individuals. Simply reporting the facts would have been a better article as far as I'm concerned.
I do feel shorts are usually more emphatic regarding information than are longs. (message boards removed from the equation) The risk is greater for shorts therefore they must be more convincing with their opinions. Or maybe just more convinced of their opinions.
My views of the article you posted:
Completely irresponsible reporting. How can scripts be measured by the first 2 months availability, either good or bad?
Quoting someone that is short as saying the results are bad is like a fox news reporter saying the president is doing a poor job.
By the same logic asking someone who is long is no different. They are going to spin things their own way.
It would be nice if adam got independent unbiased opinions but it has been my experience that he seems to have agendas with what he writes. I don't think he spun this particular article one way or the other, I just think his sources are not the least bit credible.
OMER resumed trading @ $4.91
AVNR
It is nothing new.
This Registration Statement on Form S-8 is being filed by the registrant to register (i) 4,255,003 shares of Common Stock issuable under the registrant’s 2003 Equity Incentive Plan (the “2003 Plan”), which shares represent the previously approved and announced “evergreen” increase under the 2003 Plan for calendar year 2011 and (ii) 325,000 shares of Common Stock issuable under the registrant’s 2005 Equity Incentive Plan (the “2005 Plan”), which shares represent the previously approved and announced “evergreen” increase under the 2005 Plan for fiscal year 2011.
I have not found any information on new layoffs. Just bad sales and earnings.
DEPO and AVNR both had strong trading days.
DEPO up over 3% closed above very important $10 resistance with nearly 2 million shares traded. Up $1.10 from low last Wednesday
AVNR up almost 4.5% with nearly 8.5 million shares traded
DEPO
HOD $10.16 over 1 million shares. Has been looking great lately.
DEPO @ $10.00
Haven't seen any news.
DEPO trading very nicely today.
Up $.50
5.5%
over 1 million shares.
As they say, if you ain't first the view never changes.....
CORT
Trade pre-market @ $5.19 ...... 500 shares.
Nothing in this world sucks as much as waking up and finding redfisher on top of you. 1 point, 1 stinkin point. Wrong Busch........... I picked the wrong *#^*($& Busch. Damn that's an unattractive start to the day.
Then of course I saw the weather forcast and it looks like snow is coming on April 1st. Please tell me this whole morning has been an early April Fool's Day joke.
I'm going back to sleep. Give me a wakeup call Sunday, around noon.
48 99 22
Can I just pick last names and get every driver with that name? Huh? Can I huh?
Do you mean CORT ?
$heff, you are still not back in AVNR, correct?
I jumped back on the 2nd @ $3.55
Doubt that, it only dropped $.23 or less than 6%. Certainly within normal trading ranges for a small biotech.
Isn't that what I said????
No, no, no.....
If you are in the top ten then you are a stinkin Nascar genious. You don't move into that neighborhood without doing homework day and night. I wouldn't be surprised if the people in the top ten now stay there all year, they are just a bunch of superior beings..... ;)
I was out all day, didn't see any of the race. Came home and looked at the results.....
I got 1,2,3....
I got 1,2,3....
I got 1,2,3....
Probably won't be able to type that again all year so I figured I'd make the most of it.